Chugai
Manufacturing · Japan · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
2-1-1 Nihonbashi Muromachi, Chuo-ku, Tok...Phone Number
+81 332816611Website
www.chugai-pharm.co.jpRevenue
$8 BillionStock Symbol
4519Industry
About Chugai
Chugai Org Chart
Group of Supplier Strategy, Procurement Head
Group Head of Treasury
Group of Business Planning & Management Head ...
Group Head of Risk, Management
Is Chugai your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Chugai, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Chugai had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Chugai is spiking on competitors!
Product Launch: Get notified when Chugai launches new products
Check if Chugai has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Chugai has new funding data
Earning: See what the market has to say on Chugai recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Chugai
Recommended Actions
Reach out to Masked Content who joined Chugai as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Chugai is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Chugai is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Chugai.
Chugai Tech Stack
A closer look at the technologies used by Chugai
Most Recent Scoops
Chugai News & Media
Renalys Pharma to be Acquired by Chugai Pharmaceutical
TOKYO, Oct. 24, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Tokyo; Representative Director Chaiman & CEO; BT Slingsby; "Renalys") and Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo; President & CEO: Osamu Okuda; "Chugai") today announced a definitive stock purchase...Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
SAN JOSE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. ("Chugai") for the development and commercialization of an oral product consisting of Rani’s oral delivery technology, the RaniPill®, and Chugai’s rare diseaChugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases
Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Chugai
Chugai Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company headquartered in Tokyo, Japan, dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address significant unmet medical needs. The company is widely recognized for its advanced drug discovery capabilities, particularly its proprietary a... Read More